Showing results (61-70 of 87) with videos related to

Sort By:
Pageof 9
Emerging Infectious Diseases|June 5, 2003
Leptospirosis in "Eco-Challenge" athletes, Malaysian Borneo, 2000James Sejvar, Elizabeth Bancroft, Kevin Winthrop, et al.
Rheumatology and Therapy|December 31, 2021
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 TrialsGerd R Burmester, Kevin Winthrop, Ricardo Blanco, et al.
Research Square|February 13, 2026
Lung microbial dysregulation and TNF inhibition contribute to worsened nontuberculous mycobacterial lung diseaseEthan Napier, Isaac Cinco, Ethan Stuart, et al.
American Journal of Clinical Dermatology|June 18, 2024
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of ExposureEric L Simpson, Jonathan I Silverberg, Audrey Nosbaum, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusKenneth C Kalunian, Richard Furie, Eric F Morand, et al.
Annals of the Rheumatic Diseases|February 11, 2025
Efficacy of Janus kinase inhibitors in immune-mediated inflammatory diseases a systematic literature review informing the 2024 update of an international consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
RMD Open|November 14, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature researchAndreas Kerschbaumer, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases|February 11, 2025
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases - a systematic literature review informing the 2024 update of an international expert consensus statementVictoria Konzett, Josef S Smolen, Peter Nash, et al.
Archives of Dermatological Research|October 28, 2022
The "Understanding Pyoderma Gangrenosum, Review and Assessment of Disease Effects (UPGRADE)" Project: a protocol for the development of the core outcome domain set for trials in pyoderma gangrenosumJonathan Rick, Lisa J Gould, Angelo Valerio Marzano, et al.
Neurology and Therapy|March 14, 2022
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with OfatumumabAnne H Cross, Silvia Delgado, Mario Habek, et al.
Pageof 9